EGFR and non-small cell lung carcinoma: A phase III open-label CAURAL trial (NCT02454933) investigated osimertinib plus durvalumab versus osimertinib monotherapy in patients with sensitizing EGFR-TKI and EGFR T790M mutation-positive advanced NSCLC and disease progression after EGFR-TKI therapy [67].